Company Overview
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware.
Why Investors Should Care
Return on capital employed stands at 103.8%.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +37.15% |
| 6 Months: | +100.58% |
| 3 Months: | -19.86% |
| 1 Month: | -3.07% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)48.62 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Healthy ROCE of 103.8%.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NRXP NRx Pharmaceuticals, Inc. PHARMA | 3.47 | -6.80 | $150.24M | 0.00% | 103.85% | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | 0 | 0 | 242.00K | 983.00K | 1.07M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | 97.00K | 408.00K | 631.00K |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | 145.00K | 575.00K | 437.00K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.75M | 3.73M | 4.17M | 5.20M | 5.18M |
| Operating Income | -134.48K | -192.37K | -271.81K | -220.24K | -163.18K | -175.74K | -183.31K | -119.30K | 104.82K | -5.15M | -25.61M | -17.12M | -20.10M | -15.71M | -9.60M | -9.14M | -3.85M | -8.19M | -5.81M | -6.00M | -7.05M | -3.02M | - | -3.75M | -3.73M | -4.02M | -4.62M | -4.75M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -5.51M | -17.58M | -5.85M | 1.13M | -1.03M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 671.00K | 233.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -5.51M | -17.58M | -5.89M | 360.00K | -1.43M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -105.03K | 15.48K | -6.60K | 28.08K | 187.97K | 176.02K | 59.20K | -1.59M | 102.29K | -5.16M | -25.49M | -117.00K | -37.05M | -13.45M | -6.98M | -9.08M | -5.51M | -8.72M | -6.06M | -6.53M | -7.90M | -1.62M | - | -5.51M | -17.58M | -5.89M | 360.00K | -1.43M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | -0.15 | -0.71 | -0.41 | -0.72 | -0.21 | -0.11 | -0.14 | -1.66 | -0.12 | -0.07 | -0.74 | - | - | - | -0.34 | -0.98 | -0.27 | - | -0.04 |
| R&D Expense | - | - | - | - | - | - | - | - | 1.39M | 4.33M | 2.91M | 4.66M | 6.28M | 5.48M | 2.96M | 4.13M | 804.00K | 3.87M | 3.31M | 1.75M | 2.80M | 611.00K | - | 804.00K | 987.00K | 1.43M | - | 1.31M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 0 | 0 | 0 | 1.23M |
| Cost of Revenue | - | - | - | - | - | - | 0 | 505.00K |
| Gross Profit | - | - | - | - | - | - | 0 | 720.00K |
| Operating Expenses | - | - | - | - | 44.34M | 27.59M | 18.50M | 16.94M |
| Operating Income | -1.01M | -713.19K | -51.39M | - | -44.34M | -27.59M | -18.50M | -16.22M |
| EBITDA | - | - | - | - | -39.75M | -30.02M | -24.89M | -27.81M |
| Interest Expense | - | - | - | - | 0 | 120.00K | 230.00K | 671.00K |
| Pretax Income | - | - | - | - | -39.75M | -30.15M | -25.13M | -28.62M |
| Tax Provision | - | - | - | 0 | 0 | - | - | - |
| Net Income | 66.10K | 408.43K | -51.78M | - | -39.75M | -30.15M | -25.13M | -28.62M |
| Diluted EPS | - | - | -1.51 | - | -6.10 | -3.98 | -2.36 | -1.34 |
| R&D Expense | - | - | 10.62M | 20.26M | 17.03M | 13.37M | 6.20M | 3.78M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Sep 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 69.57M | 70.80M | 32.07M | 2.94M | - | 25.82M | 7.32M | 3.65M | 12.96M |
| Current Assets | - | - | - | - | - | - | 25.80M | 6.88M | 3.30M | 8.89M |
| Cash & Equivalents | - | - | - | - | - | - | 20.05M | 4.59M | 1.44M | 7.80M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | 0 | - | - | 0 | 161.00K |
| Total Liabilities | - | 93.17K | 1.26M | 2.57M | 46.71M | - | 18.41M | 19.05M | 26.87M | 28.89M |
| Current Liabilities | - | 93.17K | 567.41K | 622.44K | 46.16M | - | 15.59M | 19.05M | 21.86M | 28.58M |
| Long Term Debt | - | - | - | - | - | - | 2.82M | - | 5.01M | - |
| Total Debt | - | - | - | - | - | - | 10.53M | 9.16M | 6.58M | 631.00K |
| Total Equity | 0 | 5.00M | 5.00M | -4.84M | -43.77M | - | 7.41M | -11.73M | -23.22M | -15.94M |
| Shares Outstanding | - | - | - | - | - | - | 6.64M | 8.39M | 14.59M | 31.73M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -473.19K | -792.73K | -2.27M | - | -39.76M | -21.66M | -10.64M | -14.11M |
| Investing Cash Flow | -647.39K | 40.25M | -2.00K | - | -10.00K | -3.00K | 0 | -2.81M |
| Financing Cash Flow | 682.50K | -39.46M | 3.25M | - | 32.21M | 6.20M | 7.49M | 23.28M |
| Capital Expenditure | - | - | - | -7.00K | -10.00K | -3.00K | - | - |
| Free Cash Flow | - | - | - | - | -39.77M | -21.66M | -10.64M | -14.11M |
| Net Change in Cash | - | - | - | - | -7.55M | -15.46M | -3.15M | 6.35M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | 58.8% |
| Operating Margin % | - | - | - | - | - | - | - | -1,324.4% |
| Net Margin % | - | - | - | - | - | - | - | -2,336.5% |
| ROE % | 1.3% | -8.4% | 118.3% | - | -536.6% | 257.0% | 108.2% | 179.6% |
| ROCE % | -1.4% | -2.3% | 118.9% | - | -433.3% | 235.1% | 101.6% | 103.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | B Group, Inc. | 9.45% | 4.09M | $13.58M |
| 2 | Vanguard Capital Management LLC | 3.74% | 1.62M | $5.37M |
| 3 | Ameriprise Financial, Inc. | 2.15% | 928.73K | $3.08M |
| 4 | Balyasny Asset Management LP | 2.06% | 893.86K | $2.97M |
| 5 | Citadel Advisors Llc | 1.57% | 680.04K | $2.26M |
| 6 | AdvisorShares Investments, LLC | 1.52% | 659.02K | $2.19M |
| 7 | Commonwealth Equity Services, LLC | 1.05% | 454.42K | $1.51M |
| 8 | UBS Group AG | 0.98% | 423.12K | $1.40M |
| 9 | Geode Capital Management, LLC | 0.73% | 314.66K | $1.04M |
| 10 | Blackrock Inc. | 0.51% | 220.46K | $731.93K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NRXP
NRx Pharmaceuticals to Participate in Upcoming Investor Conferences
WILMINGTON, Del., Sept. 08, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that the management team will participate in…
NRX Pharmaceuticals Inc (NRXP) (Q2 2026) Earnings Call Highlights: Advancing Ketamine Pipeline ...
NRX Pharmaceuticals reports improved net loss, strong cash position, and key regulatory progress for its ketamine and CNS pipeline.
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET
Key recent and second quarter highlights include: Completed first-cycle FDA review of the Company’s ANDA for preservative-free ketamine with no drug-related major deficiencies. The sole remaining item, a manufacturer's attestation on the vi…
NRx Pharmaceuticals, Inc. (NRXP) Reports Q2 Loss, Misses Revenue Estimates
NRx Pharmaceuticals (NRXP) delivered earnings and revenue surprises of -100.00% and -54.13%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
NRx Pharmaceuticals Nears FDA Decision on Preservative-Free Ketamine After Review Clears Hurdles
NRx Pharmaceuticals (NASDAQ:NRXP) said it has completed the first-cycle U.S. Food and Drug Administration review of its abbreviated new drug application, or ANDA, for preservative-free ketamine, with one remaining issue related to the produ…
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans
Conference Call 8:30 a.m. ET, Monday, August 10, 2026MIAMI, Aug. 07, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that …
NRXP — Frequently Asked Questions
What is the current share price of NRx Pharmaceuticals, Inc. (NRXP)?
As of 2026-09-19 21:16 PDT, NRx Pharmaceuticals, Inc. (NRXP) trades at $3.47 on NasdaqCM. Its 52-week range is $1.68 to $4.62.
What is the market capitalisation of NRXP?
NRx Pharmaceuticals, Inc. (NRXP) has a market capitalisation of $150.24M on NasdaqCM.
What is the P/E ratio of NRXP?
NRXP trades at a trailing price-to-earnings (P/E) ratio of -6.80. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -830.00.
Is NRXP a good stock to buy?
This page provides a data-driven analysis of NRx Pharmaceuticals, Inc. (NRXP), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.